University of Chicago

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).

796 total trials 158 currently recruiting 451 completed early-phase tilt top decile by trial count

University of Chicago: 796 sponsored US clinical trials, 158 recruiting.

University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.

Top-decile sponsor footprint

University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

796 total, page 6 of 16

COMPLETED Early Phase 1

Social Effects of Alcohol

NCT05826951
TERMINATED Phase 1

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

NCT05679388
TERMINATED Phase 1

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

NCT05276492
COMPLETED NA

Social Network Diffusion of COVID-19 Prevention for Diverse Criminal Legal Involved Communities

NCT05500274
COMPLETED Phase 4

HF Patients With LVADs Being Treated With SGLT2i

NCT05278962
COMPLETED Early Phase 1

Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function

NCT05379959
COMPLETED Phase 1

Novel Desensitization Kidney Transplantation

NCT05345717
COMPLETED Phase 2

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

NCT04978428
COMPLETED

Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients

NCT07580937
TERMINATED NA

Diabetic Fibular Nail Study

NCT05204485
TERMINATED NA

A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge

NCT04920045
COMPLETED NA

Pocket Sized Ultrasound (PsUS) and Pediatric Elbow Fractures

NCT05870345
COMPLETED Phase 2

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

NCT05041062
COMPLETED Phase 1

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

NCT05138757
COMPLETED NA

Genicular Artery Embolization to Reduce Pain Associated With Unilateral Mild to Moderate Osteoarthritis

NCT04592562
COMPLETED NA

Babies' Expectations About Racial Interactions

NCT05324007
TERMINATED Phase 1

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

NCT04722601
COMPLETED NA

Engaging and Activating Cancer Survivors in Genetic Services Study

NCT04455698
COMPLETED Early Phase 1

Drug Effects on Interpersonal Interaction

NCT05123716
COMPLETED NA

My Diabetes, My Community

NCT04970810
COMPLETED NA

Family Supports and Beliefs Survey

NCT04971265
COMPLETED Early Phase 1

Brain Function and EEG

NCT05003076
COMPLETED Phase 2

Memantine in Body Focused Repetitive Behaviors

NCT04792645
COMPLETED NA

I-COPE Study: Opioid Use and Pain Management in Older Adults

NCT04878562
COMPLETED NA

CB3 Pilot (Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia)

NCT05697380
TERMINATED NA

Prescribed Sternal Precautions vs. Self-Guided Restrictive Care (PEEERC)

NCT05206929
TERMINATED NA

Pudendal vs Caudal Block for Pediatric Penile Surgery

NCT04840654
COMPLETED NA

Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US

NCT04743908
COMPLETED

Conduction System Pacing International Registry (CONSPIRE)

NCT04831125
TERMINATED

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

NCT04827563
COMPLETED NA

Can Vitamin D Reduce the Burden of COVID-19?

NCT07128069
COMPLETED NA

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

NCT04868903
COMPLETED Early Phase 1

Drugs Brain and Behavior (DDP)

NCT04642820
TERMINATED Phase 4

Implications of Anesthetics on Sleep Consolidation

NCT04329091
COMPLETED Phase 1

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

NCT04572100
TERMINATED Phase 2

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

NCT04479358
TERMINATED NA

Ambulation With Labor Epidural in Obese Women

NCT04504682
COMPLETED NA

Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)

NCT04427202
COMPLETED NA

Virtual Teach to Goal vs. Brief Intervention Inhaler Study-outpatient

NCT04470180
COMPLETED NA

SIESTA (Sleep of Inpatients: Empower Staff to Act) for Acute Stroke Rehabilitation

NCT04254484
COMPLETED Early Phase 1

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

NCT04341129
COMPLETED NA

Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients

NCT04954157
TERMINATED Phase 1

Leflunomide in Mild COVID-19 Patients

NCT04361214
COMPLETED Phase 1

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

NCT04351620
COMPLETED Early Phase 1

COVID-19 Convalescent Plasma

NCT04340050
TERMINATED NA

Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease

NCT04207320
COMPLETED Phase 2

Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis

NCT04331795
COMPLETED Early Phase 1

Age-Related Effects of THC

NCT04294966
COMPLETED

Diaphragm Ultrasound Measurements With Variations in Modes of Ventilation

NCT04319939
COMPLETED NA

Investigating the Utility of Remote Index of Microvascular Resistance in Patients With Chronic Total Occlusion

NCT04226326
← Previous Page 6 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 137
Phase 2 156
Phase 3 14
Phase 4 53

Therapeutic Areas

Prostate Cancer 11
Head and Neck Cancer 8
Multiple Myeloma 6
Breast Cancer 6
COVID-19 5
Type 2 Diabetes 4
Kidney Stone 4
Surgery 4
Diabetes Mellitus, Type 1 4
Colorectal Cancer 4

What is open in the University of Chicago pipeline

158 recruiting of 796 indexed (20% open); 451 completed (57%).

Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Chicago: open-pipeline peers nationwide

Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of UtahUniversity of Texas Southwestern Medical CenterAcera SurgicalAlign TechnologyAltruBioAlvernia University
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 796 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Chicago page

796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.

  • 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.